127 reports of this reaction
1.9% of all AMLODIPINE AND ATORVASTATIN reports
#10 most reported adverse reaction
HEADACHE is the #10 most commonly reported adverse reaction for AMLODIPINE AND ATORVASTATIN, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 127 FDA adverse event reports linking AMLODIPINE AND ATORVASTATIN to HEADACHE. This represents approximately 1.9% of all 6,537 adverse event reports for this drug.
Patients taking AMLODIPINE AND ATORVASTATIN who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for AMLODIPINE AND ATORVASTATIN, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for AMLODIPINE AND ATORVASTATIN:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 127 FDA reports for AMLODIPINE AND ATORVASTATIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 1.9% of all adverse event reports for AMLODIPINE AND ATORVASTATIN, making it a notable side effect.
If you experience headache while taking AMLODIPINE AND ATORVASTATIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.